Positive control drugs are often treated as reference treatments in preclinical pharmacology, a group included because a protocol template asks for one. Their role is wider than that. A well-chosen positive control shows that an autoimmune disease model is pharmacologically responsive, that the endpoints in use can detect a treatment effect, and that a negative result from an investigational compound can be read with some confidence.

Without an appropriate positive control, a lack of efficacy is ambiguous. It may reflect failure of the test article, or a limitation of the model itself, and the study design usually offers no way to tell the two apart after the fact. This is why positive controls belong in efficacy study design for autoimmune and inflammatory models rather than in the administrative margin of it.
The Role of Different Control Groups
Several types of control group appear in autoimmune efficacy studies, each answering a different question.
The normal control establishes the physiological baseline, and the model control confirms that disease induction worked. A vehicle control evaluates effects introduced by the formulation, solvent or dosing procedure. Where monoclonal antibodies, bispecific antibodies or fusion proteins are involved, an isotype control may be added to separate target-specific activity from non-specific antibody effects.
The positive control serves a different purpose. It does not validate disease induction. It validates pharmacological responsiveness under the specific conditions of that experiment.
In simple terms:
- Model control: Was the disease successfully induced?
- Positive control: Can this model respond to therapeutic intervention?
The distinction matters most when a novel candidate produces an ambiguous result, because the two controls answer questions that are easy to confuse in a study report.
Why Positive Controls Are Critical in Autoimmune Models
Autoimmune disease models are variable by nature. Standardized protocols reduce the spread but do not remove it, and disease severity, onset and progression can differ between experiments run to the same written design.
For example:
- Collagen-induced arthritis (CIA) can be influenced by animal strain, collagen source, adjuvant formulation, and disease synchronization.
- Experimental autoimmune encephalomyelitis (EAE) is sensitive to antigen composition, adjuvant selection, animal sex, and treatment timing.
- DSS-induced colitis varies with DSS batch, concentration, drinking behavior, and intestinal microbiota.
- Imiquimod (IMQ)-induced psoriasis-like dermatitis depends on application area, dosing duration, and baseline skin condition.
Because of this biological variability, disease induction alone does not guarantee that a model is suitable for efficacy evaluation. A model can be reliably arthritic and still be a poor instrument for measuring a drug effect.
When a positive control produces the expected response, investigators gain confidence that:
- the model was pharmacologically responsive;
- study endpoints were sufficiently sensitive;
- the treatment window was appropriate; and
- experimental conditions were capable of detecting therapeutic effects.
Conversely, failure of the positive control should prompt a review of study design before anyone concludes that the investigational drug lacks efficacy. Disease severity, dosing schedule, endpoint selection or insufficient drug exposure can each produce an apparent negative outcome, and each is correctable.
Positive Controls Help Define the Therapeutic Window
An effective disease model needs enough dynamic range to detect a treatment effect. More severe disease is not automatically better disease.
When inflammation or tissue injury is far advanced, even clinically active therapies may produce only modest improvement, because the measurable room for improvement has already closed. At the other end, models that are too mild cannot separate active treatment from spontaneous recovery.
Positive controls therefore help establish whether disease severity falls inside a usable therapeutic window. They provide practical evidence that the model is neither underdeveloped nor excessively aggressive for the question being asked.
This matters most for chronic autoimmune disorders, where treatment typically starts after disease is established rather than during induction. A model built for prophylactic dosing answers a different question from the one the clinical program will face.
Selecting an Appropriate Positive Control
Choosing a positive control takes more thought than picking an approved therapy for the matching clinical indication.
A clinically effective drug may fail as a reference in a particular animal model because:
- the therapeutic target is not conserved across species;
- the mechanism does not align with the model biology;
- efficacy depends on disease stage;
- the evaluated endpoints do not reflect the drug's primary pharmacology.
A therapeutic human monoclonal antibody without cross-reactivity to the murine target is the clearest case. It is generally unsuitable for conventional mouse models, and investigators then need surrogate antibodies, genetically humanized models or an alternative animal species.
An ideal positive control should be compatible with three key factors:
- the biological mechanism of the disease model;
- the experimental species; and
- the selected efficacy endpoints.

Common Positive Controls Across Autoimmune Disease Models
No universal reference drug exists. Several therapeutic classes are used routinely, chosen by disease mechanism and study objective.
Arthritis Models
For CIA, CAIA, or AIA models, commonly used positive controls include:
- methotrexate;
- corticosteroids;
- anti-TNF pathway agents; and
- IL-6 pathway inhibitors.
The optimal choice depends on disease stage and study objectives. Where a candidate requires a species with a cross-reactive target, Prisys Biotech's Rheumatoid Arthritis/CIA platform provides the primate setting for the same comparison.
Psoriasis-like Skin Models
For IMQ-induced psoriasis-like dermatitis, reference treatments may include:
- topical or systemic corticosteroids;
- IL-17 or IL-23 pathway inhibitors;
- JAK/TYK2 inhibitors; and
- topical anti-inflammatory agents.
IBD Models
For DSS, TNBS, or T-cell transfer colitis models, positive controls frequently include:
- mesalazine;
- sulfasalazine;
- corticosteroids;
- anti-TNF agents;
- JAK inhibitors; or
- S1P receptor modulators.
Primate work in this indication runs through the Inflammatory Bowel Disease IBD NHP Model, where the same reference logic applies to a species whose gut physiology and immune repertoire sit closer to humans.
Atopic Dermatitis Models
For MC903, oxazolone, or DNCB-induced dermatitis models, commonly used references include:
- dexamethasone;
- tacrolimus;
- cyclosporine; and
- agents targeting IL-4/IL-13, JAK, PDE4, or TSLP pathways.
Atopic dermatitis programs that move into primates face the same question in a different species, and the reference drug has to be re-justified rather than carried over.
Multiple Sclerosis Models
In EAE studies, positive controls often include:
- fingolimod;
- glatiramer acetate; and
- methylprednisolone.
For this model, treatment timing is particularly important because preventive dosing and therapeutic dosing may produce substantially different efficacy profiles. The Multiple Sclerosis/EAE platform carries that timing question into a primate setting, where the dosing schedule has to mirror the intended clinical use for the data to mean anything.
Common Mistakes When Using Positive Controls
Several errors reduce the value of a positive control group, and most of them are avoidable at the design stage.
One common mistake is selecting a positive control on the basis of clinical indication alone while overlooking species-specific target recognition. The reference drug may be the standard of care in patients and still be pharmacologically silent in the model.
Another is treating dexamethasone as a universal reference. Corticosteroids produce broad anti-inflammatory effects, which makes them convenient, but they may not adequately evaluate therapies targeting mechanisms such as B-cell biology, complement activation, FcRn recycling, Type 2 inflammation, or tissue fibrosis. A broad immunosuppressant can make almost any model look responsive without demonstrating that the endpoint can resolve the mechanism under test.
Investigators may also administer excessively high doses that suppress disease activity almost completely, leaving insufficient dynamic range for comparing investigational therapies. The positive control then proves that the model can collapse, not that it can discriminate.
Finally, preventive dosing schedules are sometimes used even though the intended clinical application involves treatment of established disease. Such designs may overestimate efficacy and reduce translational relevance, and the gap tends to surface later, when the clinical study doses patients who already have disease.
Designing a Scientifically Informative Positive Control Group
A positive control group should be designed with the same rigor as the investigational treatment groups, which means the same attention to dose rationale, route, schedule and endpoint definition.
Several practical questions should be considered during study planning:
- Is there published or internal evidence supporting this positive control in the selected model?
- Does the selected dose demonstrate efficacy without excessive immunosuppression or toxicity?
- Is the administration route clinically and experimentally appropriate?
- Does the dosing schedule reflect preventive or therapeutic treatment objectives?
- Are the selected endpoints expected to capture the drug's mechanism of action?
- Should PK, PD, biomarker analysis, or histopathology be incorporated to strengthen interpretation?
Answering these questions early improves study interpretability and reduces the risk of ambiguous outcomes. It also shortens the discussion that follows a study, since the reference arm either did what was expected or the reason it did not is already documented.
Positive Controls as Part of the Evidence Framework
Positive controls are not protocol requirements or regulatory checkboxes. They form part of the evidence framework that supports interpretation of an efficacy study. Alongside disease induction, pharmacodynamic endpoints, exposure data and histopathology, they help determine whether an observed treatment effect is biologically meaningful.
At Prisys Biotech, positive controls are incorporated into study design according to disease mechanism, species characteristics, study objectives and endpoint selection. The work sits within the company's Immunology & Inflammation portfolio, where model choice and reference drug are planned together rather than in sequence. That approach helps efficacy studies produce interpretable data suitable for translational decisions.
Conclusion
Positive control drugs do more than provide a benchmark for comparison. They establish whether an autoimmune disease model is pharmacologically responsive, confirm that study endpoints can detect treatment effects, and improve confidence when interpreting both positive and negative findings.
A carefully selected positive control strengthens the credibility of an efficacy study, allows comparison across experimental batches, and gives stronger evidence for advancing or discontinuing a therapeutic candidate. In autoimmune pharmacology, selecting the right positive control is part of sound experimental design rather than a routine procedural step.
What is the difference between a model control and a positive control?
A: A model control confirms successful disease induction by showing the untreated disease phenotype. A positive control demonstrates that the model can respond to a known therapeutic intervention under the specific experimental conditions, providing evidence that the study is capable of detecting pharmacological efficacy.
Can any approved drug be used as a positive control for an autoimmune model?
A: No. An appropriate positive control must be compatible with the model mechanism, animal species, and study endpoints. Clinical efficacy alone is insufficient, as species-specific target recognition, disease stage, and pharmacological mechanism all influence whether a drug functions as a reliable reference in preclinical models.
Why does treatment timing matter for positive controls?
A: Many autoimmune models evolve through distinct phases of disease initiation and progression. A drug administered before disease onset may produce substantially different effects from the same drug administered after disease establishment. Therefore, the dosing schedule should reflect the intended clinical use of the investigational therapy.
Is dexamethasone an appropriate universal positive control?
A: Not necessarily. While dexamethasone is effective in many inflammatory models, its broad immunosuppressive activity does not adequately represent mechanism-specific therapies targeting pathways such as TNF, IL-17, IL-23, BAFF, FcRn, or complement. Selecting a mechanism-relevant positive control generally provides more informative pharmacological comparisons.













